Similar results indicating the role of CDK4/6 inhibition in melanoma cell cycle signaling were observed in a study by Yadav et al. who showed that abemaciclib (CDK4/6 inhibitor) caused significant tumor regression in a single xenograft mouse model developed from vemurafenib resistant A375 cell lines [19]. This evidence concerns the gene CDK4 and neoplasm.